Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Sagimet Biosciences Inc. Series A Common Stock(SGMT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SGMT
09/15/2026: SGMT (4-star) is a STRONG-BUY. BUY for 105 days. Simulated Profits (68.98%). Updated daily EoD!
Sagimet Biosciences is a clinical-stage biotechnology company focused on developing denifanstat, a novel FASN inhibitor for the treatment of MASH, a chronic liver disease with high unmet demand. The company is currently driven by its success in moving its lead asset into late-stage Phase 3 clinical trials, which is its primary growth story. However, like many clinical-stage firms, it faces intense competitive pressure from other biotech players and the inherent risk that clinical outcomes may not meet regulatory standards. While the company holds a specialized scientific position, investors should expect volatility, as future success depends on trial data and potential commercialization. It is best suited for growth-oriented investors aware of these binary risks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play suitable only for investors with a high tolerance for binary clinical trial outcomes. |
| Momentum investor | Mixed fit | Momentum investors may find opportunity during clinical data readouts, provided the technical signal is positive. |
| Value investor | Weak fit | Traditional value metrics do not apply to a pre-revenue clinical-stage biotech company. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The high volatility and clinical risk profile are unsuitable for conservative, risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news regarding clinical trial results and regulatory decisions. |
| Valuation risk | High | Valuations in biotech are speculative and can swing wildly based on changes in perceived commercial potential. |
| Competition risk (MASH therapeutics) | High | Many competitors are racing to secure the first or best-in-class treatments for the MASH market. |
| Business quality | Medium | The company has a focused management team and a clear clinical plan, but lacks a diversified commercial portfolio. |
| Dividend income | Low / none | This security offers no income potential for investors. |
| Execution risk | High | The company must successfully navigate expensive, complex, and uncertain late-stage clinical trials. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 240.67% | Avg. Invested days 42 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 650.18M USD | Price to earnings Ratio - | 1Y Target Price 29.6 |
Price to earnings Ratio - | 1Y Target Price 29.6 | ||
Volume (30-day avg) 1.2M shares | Beta 3.49 | 52 Weeks Range 4.50 - 11.45 | Updated Date 09/15/2026 |
52 Weeks Range 4.50 - 11.45 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing proprietary FASN inhibitor candidates through clinical milestones for eventual commercialization. | The company currently makes no money; it spends cash to develop drugs that, if approved, could generate significant future revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 438.10M | Price to Sales(TTM) 52.5 |
Enterprise Value 438.10M | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 61.59M | Shares Floating 55.78M |
Shares Outstanding 61.59M | Shares Floating 55.78M | ||
Percent Insiders 3.35 | Percent Institutions 83.1 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquarters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.sagimet.com |
Full time employees 16 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.